CAR T-Cell Treatment for Lymphoma (CASEY Trial)

Phase 1

Waitlist Available

Led By Bilal Omer, MD

Research Sponsored by Baylor College of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up time frame 4 weeks post infusion

Awards & highlights

No Placebo-Only Group

Summary

This trial is for patients with lymph gland diseases like Hodgkin or non-Hodgkin Lymphoma. The study focuses on using special infection-fighting blood cells called T cells to target cancer cells

Who is the study for?

This trial is for patients with certain lymph gland diseases, including Hodgkin or non-Hodgkin Lymphoma, T/NK-lymphoproliferative disease, who have not responded well to existing treatments. It's particularly aimed at those whose cancer cells show signs of the Epstein Barr virus (EBV), which is linked to these conditions.

What is being tested?

The study tests a new gene therapy using modified T cells that target EBV-infected tumor cells. These T cells are engineered with a C7R gene to help them survive longer and potentially improve their ability to fight the cancer. The goal is to determine the safest high dose and its effectiveness against the cancer.

What are the potential side effects?

While specific side effects aren't listed here, similar therapies can cause immune reactions, flu-like symptoms, fatigue, fever, and in some cases more severe complications related to how the body responds to genetically modified T-cells.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ time frame 4 weeks post infusion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~time frame 4 weeks post infusion

This trial's timeline: 3 weeks for screening, Varies for treatment, and time frame 4 weeks post infusion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Dose limiting toxicity (DLT) rate

Secondary study objectives

Overall Response Rate

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment Arm AExperimental Treatment1 Intervention

Patients will initially be consented for procurement of blood for generation of the transduced T-cells. Three dose levels will be evaluated and a possible dose level -1 in case of unexpected toxicity at dose level 1. Each patient will receive one T cell infusion.

Do I qualify?Apply below to find out